Boston Scientific Corp (BSX) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Boston Scientific Corp (BSX) scores 7.0 out of 10 as of , computed from its reported financial statements. That reads as high quality. The reading rests on growth, and predictability is what holds it back.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
We cannot judge Boston Scientific Corp yet, because fewer than five years had both a return on capital and a cost of capital we could measure. This is not a “no”.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
The Quality Score for BSX stands at 7.0 out of 10 as of October 19, 2026, which puts Boston Scientific Corp in the high quality band. Businesses in this band tend to combine good returns with a sound balance sheet, even if one pillar lags the others. It rolls Boston Scientific Corp’s profitability, solvency, growth, efficiency and predictability into one number, each judged against the norms of its sector.
Among the 212 Healthcare companies with a published score, that ranks at the 89th percentile, in the top quarter of its peers. A typical company in the group scores 4.4, and the best quarter starts from 6.0. Boston Scientific Corp is well above that typical reading.
On profitability, Boston Scientific Corp scores 5.9, an average reading. Its peers have a median of 2.7 across 210 Healthcare companies, which places it well above them, at the 79th percentile. Profitability in the middle of the range is neither a moat nor a warning: margins and returns look like those of an ordinary business in this line of work.
On solvency, Boston Scientific Corp scores 7.8, a strong reading. Its peers have a median of 6.5 across 150 Healthcare companies, which places it above them, at the 65th percentile. Strong solvency points to a balance sheet that can carry its debts comfortably, with interest well covered and little pressure from creditors.
On growth, Boston Scientific Corp scores 8.5, a strong reading. Its peers have a median of 4.9 across 107 Healthcare companies, which places it well above them, at the 91st percentile. Growth at this level is valuable when it is sustained, and the predictability pillar is the place to check whether it has been steady.
On efficiency, Boston Scientific Corp scores 7.3, a strong reading. Its peers have a median of 6.0 across 200 Healthcare companies, which places it above them, at the 69th percentile. High efficiency means assets and earnings are being turned into cash and output better than at most peers, a sign of a well run operation.
Predictability scores 5.8 out of 10, which reads as average. The median across 207 Healthcare companies is 3.4, so Boston Scientific Corp is well above its peers on this pillar and ranks at the 79th percentile. An average predictability reading means results have wobbled about as much as is normal for the sector.
Growth at 8.5 is Boston Scientific Corp’s best pillar and predictability at 5.8 its weakest. The 2.7 point gap between them is worth keeping in mind when reading the overall. Leading with growth is attractive as long as the expansion is earning a decent return. Uneven results make any single year a weaker guide to the next one.
Boston Scientific Corp has no pillar below the median of Healthcare companies, which leaves little room to rise. Its exposure is to slippage instead, and profitability carries the most weight: one point less there would mean an overall of roughly 6.8 rather than 7.0. The weights add up to 100 points (profitability 25, solvency 20, growth 20, efficiency 15, predictability 20), and Boston Scientific Corp has a reading on every pillar.
For a fair comparison, start with companies of a similar size: the Healthcare companies below are nearest to Boston Scientific Corp by market value, each scored on the same pillars.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Boston Scientific Corp scores 7.0 out of 10, which reads as high quality. Its strongest pillar is growth, its weakest is predictability. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Boston Scientific Corp ranks at the 89th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Boston Scientific Corp’s 7.0.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for BSX are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card